Editas Medicine (EDIT) Earnings Date, Estimates & Call Transcripts $2.80 +0.07 (+2.56%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$2.80 +0.01 (+0.18%) As of 08/22/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Editas Medicine Earnings Summary Editas Medicine posted Q2 2025 earnings on August 12, 2025, reporting an EPS of -$0.63, which missed the consensus estimate of -$0.41 by $0.22. Quarterly revenue was reported to be $3.58 million, above analysts' expectations of $1.81 million. With a trailing EPS of -$2.85, Editas Medicine's earnings are expected to grow next year, from ($2.71) to ($1.66) per share. Upcoming Q3 Earnings DateNov. 3Before Market OpensEstimatedConsensus EPS (Aug. 12) -$0.41 Actual EPS (Aug. 12) -$0.63 Missed By -$0.22 Actual Revenue (Aug. 12) $3.58MQ2 2025 Earnings ResourcesQ2 2025 Earnings Report Press Release (8-K) Quarterly Report (10-Q)EDIT Upcoming EarningsEditas Medicine's next earnings date is estimated for Monday, November 3, 2025, based on past reporting schedules. Powered by Get Editas Medicine Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Editas Medicine and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataEDIT Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.EDIT Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Editas Medicine Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20253-$0.63-$0.46-$0.55Q2 20253-$0.46-$0.33-$0.37Q3 20253-$0.43-$0.14-$0.33Q4 20253-$0.38-$0.14-$0.24 FY 2025 12 -$1.90 -$1.07 -$1.49 Q1 20262-$0.47-$0.45-$0.46Q2 20262-$0.47-$0.39-$0.43Q3 20262-$0.48-$0.46-$0.47Q4 20262-$0.47-$0.18-$0.33 FY 2026 8 -$1.89 -$1.48 -$1.69 Q1 20271-$0.48-$0.48-$0.48 Editas Medicine Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame Start Date End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails 11/3/2025(Estimated)--------8/12/2025Q2 2025-$0.41-$0.63 -$0.22-$0.63$1.81M$3.58M5/12/2025Q1 2025-$0.51-$0.43+$0.08-$0.92$0.79M$4.66M3/5/2025Q4 2024-$0.39-$0.55 -$0.16-$0.55$37.17M$30.60M11/4/2024Q3 2024-$0.75-$0.75--$0.75$3.93M$0.06M8/7/2024Q2 2024-$0.70-$0.82 -$0.12-$0.82$4.78M$0.51M5/8/2024Q1 2024-$0.63-$0.76 -$0.13-$0.76$11.14M$1.10M2/28/2024Q4 2023-$0.52-$0.23+$0.29-$0.23$4.84M$60.00M11/3/2023Q3 2023-$0.64-$0.55+$0.09-$0.55$3.70M$5.34M Editas Medicine Earnings - Frequently Asked Questions When is Editas Medicine's earnings date? Editas Medicine has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, November 3rd, 2025 based off last year's report dates. Learn more on EDIT's earnings history. Did Editas Medicine beat their earnings estimates last quarter? In the previous quarter, Editas Medicine (NASDAQ:EDIT) missed the analysts' consensus estimate of ($0.41) by $0.22 with a reported earnings per share (EPS) of ($0.63). Learn more on analysts' earnings estimate vs. EDIT's actual earnings. How much revenue does Editas Medicine generate each year? Editas Medicine (NASDAQ:EDIT) has a recorded annual revenue of $32.31 million. How much profit does Editas Medicine generate each year? Editas Medicine (NASDAQ:EDIT) has a recorded net income of -$237.09 million. EDIT has generated -$2.85 earnings per share over the last four quarters. What is Editas Medicine's EPS forecast for next year? Editas Medicine's earnings are expected to grow from ($2.71) per share to ($1.66) per share in the next year. More Earnings Resources from MarketBeat Related Companies Beam Therapeutics Earnings Results CRISPR Therapeutics Earnings Results Intellia Therapeutics Earnings Results Praxis Precision Medicines Earnings Results Iovance Biotherapeutics Earnings Results Oric Pharmaceuticals Earnings Results Nuvation Bio Earnings Results Upstream Bio Earnings Results Trevi Therapeutics Earnings Results Urogen Pharma Earnings Results Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles After Earnings Miss, Walmart Is Still a Top Consumer Staples PlayRoyal Caribbean Earnings Beat Fuels Strong 2025 OutlookDLocal Stock Soars 43% After Earnings Beat and Raised GuidanceGreen Dot's 30% Rally: Turnaround Takes Off on Explosive EarningsElbit Systems Jumps on Record Earnings and a $1.6B ContractBrinker Serves Up Earnings Beat, Sidesteps Cost PressuresWhy BigBear.ai Stock's Dip on Earnings Can Be an Opportunity This page (NASDAQ:EDIT) was last updated on 8/24/2025 by MarketBeat.com Staff From Our PartnersTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredGENIUS Act: Cancel Your Money?They said digital dollars were off the table. But with the GENIUS Act now federal law, private corporations—no...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Editas Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Editas Medicine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access